VolitionRx (NYSE:VNRX) Earns Buy Rating from D. Boral Capital

VolitionRx (NYSE:VNRX)‘s stock had its “buy” rating restated by equities researchers at D. Boral Capital in a research report issued to clients and investors on Thursday,Benzinga reports. They currently have a $5.00 price objective on the stock.

Several other analysts have also recently issued reports on VNRX. StockNews.com started coverage on VolitionRx in a report on Friday, January 31st. They set a “sell” rating on the stock. Benchmark reaffirmed a “hold” rating on shares of VolitionRx in a report on Friday, November 22nd.

VolitionRx Price Performance

Shares of VNRX opened at $0.60 on Thursday. The stock has a market capitalization of $55.60 million, a price-to-earnings ratio of -1.67 and a beta of 1.20. VolitionRx has a 1 year low of $0.43 and a 1 year high of $1.22. The business’s 50 day simple moving average is $0.62 and its 200-day simple moving average is $0.65.

Insider Activity at VolitionRx

In related news, CEO Cameron John Reynolds purchased 139,811 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The shares were bought at an average price of $0.57 per share, for a total transaction of $79,692.27. Following the acquisition, the chief executive officer now owns 2,117,404 shares of the company’s stock, valued at approximately $1,206,920.28. This represents a 7.07 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Guy Archibald Innes bought 174,764 shares of VolitionRx stock in a transaction on Monday, December 9th. The stock was acquired at an average price of $0.57 per share, for a total transaction of $99,615.48. Following the purchase, the director now owns 617,085 shares of the company’s stock, valued at approximately $351,738.45. This trade represents a 39.51 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 358,266 shares of company stock worth $204,212. Company insiders own 12.80% of the company’s stock.

Institutional Trading of VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Geode Capital Management LLC grew its holdings in VolitionRx Limited (NYSE:VNRX) by 15.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 730,448 shares of the company’s stock after purchasing an additional 95,900 shares during the period. Geode Capital Management LLC owned about 0.79% of VolitionRx worth $439,000 as of its most recent filing with the Securities & Exchange Commission. 8.09% of the stock is owned by institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.